絞り込み

16599

広告

1144件中 161件~180件表示    検索結果をPubMedで見る PubMedで見る

Real Clinical Practice of Using Afatinib Therapy in NSCLC Patients with an Acquired T790M Mutation.

Afatinib Plus Bevacizumab Combination After Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Multicenter, Single-Arm, Phase 2 Trial (ABC Study).

First reported case of afatinib-associated toxic megacolon.

Epithelial-to-mesenchymal transition (EMT) causing acquired resistance to afatinib in a patient with epidermal growth factor receptor ()-mutant lung adenocarcinoma.

Detection of EGFR T790M in a Large Amount of Malignant Ascites Cellblock.

Mouse avatar models of esophageal squamous cell carcinoma proved the potential for EGFR-TKI afatinib and uncovered Src family kinases involved in acquired resistance.

Clinical Activity of Pan-HER Inhibitors Against HER2-Mutant Lung Adenocarcinoma.

Tissue and Blood Biomarkers in Lung Cancer: A Review.

Author Correction: Genetically engineered cerebral organoids model brain tumor formation.

The effectiveness of afatinib and osimertinib in a Chinese patient with advanced lung adenocarcinoma harboring a rare triple EGFR mutation (R670W/H835L/L833V): a case report and literature review.

Afatinib-induced Interstitial Lung Disease Successfully Treated with Corticosteroids: Case Report and Review of the Literature.

Development and validation of an ELISA with high sensitivity for therapeutic monitoring of afatinib.

Multi-disciplinary proactive follow-up algorithm for patients with advanced NSCLC receiving afatinib.

An EGFR-mutated Lung Adenocarcinoma Undergoing Squamous Cell Carcinoma Transformation Exhibited a Durable Response to Afatinib.

Cost-effectiveness and safety of the molecular targeted drugs afatinib, gefitinib and erlotinib as first-line treatments for patients with advanced EGFR mutation-positive non-small-cell lung cancer.

Activity of Afatinib in Heavily Pretreated Patients with HER2 Mutation-Positive Advanced NSCLC: Findings from a Global Named Patient Use Program.

Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients: Meta-analysis of incidence and risk factors of EGFR-TKI pneumonitis in NSCLC.

A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors.

Osimertinib.

Afatinib.

  1. 5
  2. 6
  3. 7
  4. 8
  5. 9
  6. 10
  7. 11
  8. 12
  9. 13
  10. 14
Sort by
※並べ替えは表示に時間がかかります